Financial Ratios Dr. Sulaiman Al Habib Medical Services Group Company
Equities
4013
SA1510P1UMH1
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 237.60 SAR | -0.25% |
|
+2.86% | -7.55% |
| 02-25 | Al Rajhi Capital Cuts Dr. Sulaiman Al Habib Medical Services Group PT, Keeps at Overweight | MT |
| 02-24 | AlphaMena Raises Dr. Sulaiman Al Habib Medical Services' PT, Affirms Sell Rating | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 9.02 | 9.08 | 9.23 | 8.1 | 7.48 | |||||
Return on Total Capital | 11.24 | 11.67 | 12.14 | 10.62 | 9.77 | |||||
Return On Equity % | 26.14 | 29.04 | 32.65 | 32.96 | 31.07 | |||||
Return on Common Equity | 26.86 | 29.43 | 33.1 | 33.9 | 31.86 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 31.95 | 32.88 | 34.22 | 33.3 | 30.6 | |||||
SG&A Margin | 11.73 | 12.42 | 12.18 | 12.26 | 11.49 | |||||
EBITDA Margin % | 23.84 | 23.59 | 24.8 | 24.2 | 23.29 | |||||
EBITA Margin % | 20.22 | 20.46 | 22.04 | 21.04 | 19.11 | |||||
EBIT Margin % | 20.22 | 20.46 | 22.04 | 21.04 | 19.11 | |||||
Income From Continuing Operations Margin % | 19.13 | 20.32 | 22.1 | 21.16 | 18.18 | |||||
Net Income Margin % | 18.99 | 19.86 | 21.52 | 20.67 | 17.52 | |||||
Net Avail. For Common Margin % | 18.99 | 19.86 | 21.52 | 20.67 | 17.52 | |||||
Normalized Net Income Margin | 12.79 | 13.05 | 13.68 | 12.73 | 10.83 | |||||
Levered Free Cash Flow Margin | 3.92 | 7.12 | -13.04 | -18.91 | -7.83 | |||||
Unlevered Free Cash Flow Margin | 4.24 | 7.49 | -12.57 | -18 | -6.28 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.71 | 0.71 | 0.67 | 0.62 | 0.63 | |||||
Fixed Assets Turnover | 1.18 | 1.14 | 1 | 0.86 | 0.85 | |||||
Receivables Turnover (Average Receivables) | 8.32 | 10.13 | 13.16 | 11.82 | 9.58 | |||||
Inventory Turnover (Average Inventory) | 12.54 | 12.43 | 12.1 | 10.75 | 10.15 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.02 | 1.61 | 1.25 | 1.28 | 1.15 | |||||
Quick Ratio | 1.73 | 1.35 | 1.01 | 0.98 | 0.84 | |||||
Operating Cash Flow to Current Liabilities | 1.07 | 1.1 | 0.98 | 0.71 | 0.72 | |||||
Days Sales Outstanding (Average Receivables) | 43.89 | 36.03 | 27.73 | 30.97 | 38.08 | |||||
Days Outstanding Inventory (Average Inventory) | 29.1 | 29.36 | 30.15 | 34.05 | 35.97 | |||||
Average Days Payable Outstanding | 50.01 | 52.61 | 54.65 | 57.38 | 58.64 | |||||
Cash Conversion Cycle (Average Days) | 22.98 | 12.79 | 3.24 | 7.64 | 15.41 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 55.26 | 57.68 | 76.61 | 107.26 | 110.39 | |||||
Total Debt / Total Capital | 35.59 | 36.58 | 43.38 | 51.75 | 52.47 | |||||
LT Debt/Equity | 48.81 | 54.21 | 74.57 | 105.02 | 108.06 | |||||
Long-Term Debt / Total Capital | 31.43 | 34.38 | 42.22 | 50.67 | 51.36 | |||||
Total Liabilities / Total Assets | 48.95 | 51.48 | 57.17 | 62.97 | 63.68 | |||||
EBIT / Interest Expense | 38.69 | 34.45 | 29.89 | 14.48 | 7.73 | |||||
EBITDA / Interest Expense | 47 | 40.72 | 34.35 | 17.06 | 9.71 | |||||
(EBITDA - Capex) / Interest Expense | 13.92 | 10.06 | -15.53 | -6.46 | 0.91 | |||||
Total Debt / EBITDA | 1.72 | 1.75 | 2.15 | 2.94 | 2.83 | |||||
Net Debt / EBITDA | 0.23 | 0.39 | 1.06 | 1.9 | 2.13 | |||||
Total Debt / (EBITDA - Capex) | 5.79 | 7.09 | -4.76 | -7.77 | 30.27 | |||||
Net Debt / (EBITDA - Capex) | 0.78 | 1.56 | -2.35 | -5.02 | 22.85 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 23.69 | 14.62 | 14.41 | 17.79 | 22.38 | |||||
Gross Profit, 1 Yr. Growth % | 25.02 | 17.97 | 19.07 | 14.63 | 12.44 | |||||
EBITDA, 1 Yr. Growth % | 25.41 | 13.42 | 20.3 | 14.96 | 17.78 | |||||
EBITA, 1 Yr. Growth % | 31.51 | 15.98 | 23.24 | 12.44 | 11.15 | |||||
EBIT, 1 Yr. Growth % | 31.51 | 15.98 | 23.24 | 12.44 | 11.15 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 34.03 | 21.75 | 24.42 | 12.78 | 5.14 | |||||
Net Income, 1 Yr. Growth % | 30.43 | 19.91 | 23.94 | 13.16 | 3.72 | |||||
Normalized Net Income, 1 Yr. Growth % | 27.89 | 16.93 | 19.92 | 9.63 | 4.09 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 30.43 | 19.91 | 23.94 | 13.16 | 3.72 | |||||
Accounts Receivable, 1 Yr. Growth % | 6.51 | -17.52 | -5.2 | 65.35 | 42.13 | |||||
Inventory, 1 Yr. Growth % | 7.1 | 20.52 | 10.74 | 55.95 | 21.42 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 17.79 | 19.3 | 40.65 | 32.34 | 17.12 | |||||
Total Assets, 1 Yr. Growth % | 14.2 | 16.22 | 25.54 | 30.13 | 12.88 | |||||
Tangible Book Value, 1 Yr. Growth % | 8.7 | 10.1 | 10.32 | 10.63 | 10.13 | |||||
Common Equity, 1 Yr. Growth % | 8.7 | 10.1 | 10.32 | 10.63 | 10.13 | |||||
Cash From Operations, 1 Yr. Growth % | -2.3 | 30.28 | 14.08 | -8.44 | 14.53 | |||||
Capital Expenditures, 1 Yr. Growth % | 54 | 20.73 | 131.07 | 9.49 | -22.08 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -69.27 | 108.38 | -309.51 | 70.88 | -49.36 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -67.77 | 102.36 | -292.09 | 68.63 | -57.3 | |||||
Dividend Per Share, 1 Yr. Growth % | 33.33 | 24.29 | 24.14 | 10.42 | - | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 20.22 | 19.07 | 14.52 | 16.09 | 20.06 | |||||
Gross Profit, 2 Yr. CAGR % | 23.67 | 21.45 | 18.52 | 16.83 | 13.53 | |||||
EBITDA, 2 Yr. CAGR % | 26.87 | 19.27 | 16.81 | 17.6 | 16.36 | |||||
EBITA, 2 Yr. CAGR % | 29.99 | 23.5 | 19.56 | 17.71 | 11.79 | |||||
EBIT, 2 Yr. CAGR % | 29.99 | 23.5 | 19.56 | 17.71 | 11.79 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 28.7 | 27.74 | 23.08 | 18.46 | 8.89 | |||||
Net Income, 2 Yr. CAGR % | 25.77 | 25.06 | 21.91 | 18.43 | 8.34 | |||||
Normalized Net Income, 2 Yr. CAGR % | 24.64 | 22.29 | 18.41 | 14.66 | 6.82 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 25.77 | 25.06 | 21.91 | 18.43 | 8.34 | |||||
Accounts Receivable, 2 Yr. CAGR % | -22.76 | -6.27 | -11.58 | 26.2 | 53.3 | |||||
Inventory, 2 Yr. CAGR % | 17.27 | 13.61 | 15.53 | 31.41 | 37.61 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 13.74 | 18.54 | 29.54 | 36.43 | 24.5 | |||||
Total Assets, 2 Yr. CAGR % | 13.08 | 15.21 | 20.79 | 27.81 | 21.2 | |||||
Tangible Book Value, 2 Yr. CAGR % | 10.23 | 9.4 | 10.21 | 10.48 | 10.38 | |||||
Common Equity, 2 Yr. CAGR % | 10.23 | 9.4 | 10.21 | 10.48 | 10.38 | |||||
Cash From Operations, 2 Yr. CAGR % | 43.56 | 12.82 | 21.91 | 2.2 | 2.4 | |||||
Capital Expenditures, 2 Yr. CAGR % | 30.78 | 36.35 | 67.02 | 59.06 | -7.64 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 48.59 | -19.98 | 108.95 | 89.21 | -6.97 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 66.38 | -19.24 | 97.16 | 79.98 | -15.15 | |||||
Dividend Per Share, 2 Yr. CAGR % | - | 28.73 | 24.21 | 17.08 | - | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 16.48 | 18.33 | 17.5 | 15.6 | 18.15 | |||||
Gross Profit, 3 Yr. CAGR % | 19.63 | 21.74 | 20.65 | 17.21 | 15.35 | |||||
EBITDA, 3 Yr. CAGR % | 19.94 | 22.22 | 19.61 | 16.19 | 17.66 | |||||
EBITA, 3 Yr. CAGR % | 22.3 | 25.14 | 23.41 | 17.13 | 15.48 | |||||
EBIT, 3 Yr. CAGR % | 22.3 | 25.14 | 23.41 | 17.13 | 15.48 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 20.14 | 26.34 | 26.63 | 19.54 | 13.84 | |||||
Net Income, 3 Yr. CAGR % | 19.77 | 23.79 | 24.69 | 18.92 | 13.31 | |||||
Normalized Net Income, 3 Yr. CAGR % | 18.86 | 22.01 | 21.49 | 15.41 | 11.02 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 19.77 | 23.79 | 24.69 | 18.92 | 13.31 | |||||
Accounts Receivable, 3 Yr. CAGR % | -11.81 | -21.05 | -5.92 | 9.52 | 31.3 | |||||
Inventory, 3 Yr. CAGR % | 10.38 | 18.34 | 12.65 | 27.68 | 27.99 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 15.77 | 15.57 | 25.49 | 30.47 | 29.67 | |||||
Total Assets, 3 Yr. CAGR % | 12.81 | 14.12 | 18.55 | 23.83 | 22.63 | |||||
Tangible Book Value, 3 Yr. CAGR % | 7.25 | 10.19 | 9.71 | 10.35 | 10.36 | |||||
Common Equity, 3 Yr. CAGR % | 7.25 | 10.19 | 9.71 | 10.35 | 10.36 | |||||
Cash From Operations, 3 Yr. CAGR % | 14.68 | 38.99 | 13.24 | 10.82 | 6.16 | |||||
Capital Expenditures, 3 Yr. CAGR % | 23.96 | 27.34 | 62.56 | 45.09 | 25.39 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -16.04 | 66.32 | 10.29 | 95.4 | 21.94 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -14.48 | 77.6 | 7.81 | 87.15 | 11.41 | |||||
Dividend Per Share, 3 Yr. CAGR % | - | - | 27.18 | 19.43 | - | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 8.29 | 12.14 | 15.69 | 17.43 | 18.52 | |||||
Gross Profit, 5 Yr. CAGR % | 4.25 | 12.14 | 19.19 | 19.75 | 17.75 | |||||
EBITDA, 5 Yr. CAGR % | 9.77 | 18.54 | 18.68 | 20.35 | 18.3 | |||||
EBITA, 5 Yr. CAGR % | 9.71 | 21.69 | 21.19 | 22.11 | 18.63 | |||||
EBIT, 5 Yr. CAGR % | 9.71 | 21.69 | 21.19 | 22.11 | 18.63 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 6.56 | 20.74 | 21.3 | 23.12 | 19.21 | |||||
Net Income, 5 Yr. CAGR % | 6.39 | 20.18 | 20.62 | 21.62 | 17.87 | |||||
Normalized Net Income, 5 Yr. CAGR % | 7.2 | 18.92 | 18.68 | 19.02 | 15.4 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 6.39 | 20.18 | 20.62 | 21.62 | 17.87 | |||||
Accounts Receivable, 5 Yr. CAGR % | -14.24 | -15.16 | -11.72 | -4.76 | 14.74 | |||||
Inventory, 5 Yr. CAGR % | 9.26 | 9.71 | 12.41 | 23.41 | 22.04 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 14.01 | 16.79 | 21.09 | 23.5 | 25.1 | |||||
Total Assets, 5 Yr. CAGR % | 9.99 | 12.41 | 15.94 | 19.41 | 19.6 | |||||
Tangible Book Value, 5 Yr. CAGR % | 4.55 | 6.29 | 8.43 | 10.31 | 9.98 | |||||
Common Equity, 5 Yr. CAGR % | 4.55 | 6.29 | 8.43 | 10.31 | 9.98 | |||||
Cash From Operations, 5 Yr. CAGR % | 19.39 | 21.86 | 17.52 | 22.91 | 8.77 | |||||
Capital Expenditures, 5 Yr. CAGR % | 0.18 | 30.24 | 39.66 | 39.19 | 29.66 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -15.26 | 6.15 | 20.91 | 75.12 | 3.03 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -13.86 | 6.65 | 19.45 | 78.55 | -2.04 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















